Response Genetics to Provide GSK with PCR-Based BRAF Mutation Analysis

GSK gains certain rights to Response Genetics' PCR analysis technology and diagnostic expertise to assess BRAF mutations in human tumor samples.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.